Clinical trial · Interventional
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the investigational drug, temsirolimus, will be combined with cetuximab, a biologic agent used in the treatment of colorectal cancer. Cetuximab in combination with temsirolimus may be more effective in treating advanced colorectal cancer than cetuximab alone. The purpose of this research study is to try to define the highest dose of cetuximab that can be used safely in combination with temsirolimus to treat advanced colorectal cancer that has progressed through standard therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Adenocarcinoma | Colorectal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab | Drug | Cetuximab | ALIAS |
| Temsirolimus | Drug | Temsirolimus | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Temsirolimus Combined With Cetuximab
- interventionNames
- Drug: Temsirolimus
- Drug: Cetuximab
Primary outcomes (3)
- measure
- To determine the dose-limiting toxicities and maximal tolerated doses of cetuximab combined with temsirolimus.
- timeFrame
- 2 years
- measure
- To determine the dosing regimen appropriate for Phase 2 studies of the combination.
- timeFrame
- 2 years
- measure
- To determine the pharmacokinetics of combined treatment with cetuximab and temsirolimus.
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Previously treated metastatic colorectal adenocarcinoma, histologically proven. Subjects must have previously received and had evidence of progression on cetuximab, bevacizumab, 5FU, irinotecan, and oxaliplatin, or demonstrated intolerance to those agents (except cetuximab). * Measurable disease by RECIST criteria * ECOG Performance Status 0 or 1. * Male or female, 18 years of age or older. * Life expectancy greater than or equal to 12 weeks. * At least 2 weeks have elapsed between previous anti-cancer therapy AND resolution of any skin rash related to prior treatment with an epidermal growth factor receptor inhibitor. * Lab values within ranges as outlined in protocol Exclusion Criteria: * Diagnosis of second malignancy within the last 3 years, except for adequately treated basal cell carcinoma or squamous cell skin cancer. * Ongoing cardiac dysrhythmias of NCI CTCAE grade \>/=2, atrial fibrillation, QTc prolongation to \>450msec for males and \>470 msec for females. * Known immunodeficiency disorders or active infections requiring treatment * Pregnancy or breastfeeding * Brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease * Prior radiation therapy or major surgery within 2 weeks of study entry * Prior radiation therapy to \> 25% of the bone marrow * Treatment with other experimental or alternative therapies during the course of the trial * History of hypersensitivity to polysorbate or cetuximab
References
Publications (0)
Data not yet available